Pharma & Healthcare

Global PD-1 and PD-L1 Inhibitors Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

The global PD-1 and PD-L1 Inhibitors market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Merck KGaA
By Type: (Dominant Segment vs High-Margin Innovation)
PD-1 Inhibitors
PD-L1 Inhibitors
By Application: (Core Demand Driver vs Emerging Opportunity)
Solid Tumors
Blood-related Tumors
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Merck in Europe)
- Emerging Product Trends: PD-1 Inhibitors adoption vs. PD-L1 Inhibitors premiumization
- Demand-Side Dynamics: Solid Tumors growth in China vs. Blood-related Tumors potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
Japan
China
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of PD-1 and PD-L1 Inhibitors market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., PD-L1 Inhibitors in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Blood-related Tumors in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., PD-1 Inhibitors dominance in Europe vs. PD-L1 Inhibitors demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
1 Market Overview
1.1 PD-1 and PD-L1 Inhibitors Product Scope
1.2 PD-1 and PD-L1 Inhibitors by Type
1.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Type (2020 & 2024 & 2031)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 PD-1 and PD-L1 Inhibitors by Application
1.3.1 Global PD-1 and PD-L1 Inhibitors Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Solid Tumors
1.3.3 Blood-related Tumors
1.4 Global PD-1 and PD-L1 Inhibitors Market Estimates and Forecasts (2020-2031)
1.4.1 Global PD-1 and PD-L1 Inhibitors Market Size in Value Growth Rate (2020-2031)
1.4.2 Global PD-1 and PD-L1 Inhibitors Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global PD-1 and PD-L1 Inhibitors Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global PD-1 and PD-L1 Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global PD-1 and PD-L1 Inhibitors Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2020-2025)
2.2.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2020-2025)
2.3 Global PD-1 and PD-L1 Inhibitors Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global PD-1 and PD-L1 Inhibitors Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global PD-1 and PD-L1 Inhibitors Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America PD-1 and PD-L1 Inhibitors Market Size and Prospective (2020-2031)
2.4.2 Europe PD-1 and PD-L1 Inhibitors Market Size and Prospective (2020-2031)
2.4.3 Japan PD-1 and PD-L1 Inhibitors Market Size and Prospective (2020-2031)
2.4.4 China PD-1 and PD-L1 Inhibitors Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global PD-1 and PD-L1 Inhibitors Historic Market Review by Type (2020-2025)
3.1.1 Global PD-1 and PD-L1 Inhibitors Sales by Type (2020-2025)
3.1.2 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2020-2025)
3.1.3 Global PD-1 and PD-L1 Inhibitors Price by Type (2020-2025)
3.2 Global PD-1 and PD-L1 Inhibitors Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global PD-1 and PD-L1 Inhibitors Sales Forecast by Type (2026-2031)
3.2.2 Global PD-1 and PD-L1 Inhibitors Revenue Forecast by Type (2026-2031)
3.2.3 Global PD-1 and PD-L1 Inhibitors Price Forecast by Type (2026-2031)
3.3 Different Types PD-1 and PD-L1 Inhibitors Representative Players
4 Global Market Size by Application
4.1 Global PD-1 and PD-L1 Inhibitors Historic Market Review by Application (2020-2025)
4.1.1 Global PD-1 and PD-L1 Inhibitors Sales by Application (2020-2025)
4.1.2 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2020-2025)
4.1.3 Global PD-1 and PD-L1 Inhibitors Price by Application (2020-2025)
4.2 Global PD-1 and PD-L1 Inhibitors Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global PD-1 and PD-L1 Inhibitors Sales Forecast by Application (2026-2031)
4.2.2 Global PD-1 and PD-L1 Inhibitors Revenue Forecast by Application (2026-2031)
4.2.3 Global PD-1 and PD-L1 Inhibitors Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in PD-1 and PD-L1 Inhibitors Application
5 Competition Landscape by Players
5.1 Global PD-1 and PD-L1 Inhibitors Sales by Players (2020-2025)
5.2 Global Top PD-1 and PD-L1 Inhibitors Players by Revenue (2020-2025)
5.3 Global PD-1 and PD-L1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Inhibitors as of 2024)
5.4 Global PD-1 and PD-L1 Inhibitors Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of PD-1 and PD-L1 Inhibitors, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of PD-1 and PD-L1 Inhibitors, Product Type & Application
5.7 Global Key Manufacturers of PD-1 and PD-L1 Inhibitors, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America PD-1 and PD-L1 Inhibitors Sales by Company
6.1.1.1 North America PD-1 and PD-L1 Inhibitors Sales by Company (2020-2025)
6.1.1.2 North America PD-1 and PD-L1 Inhibitors Revenue by Company (2020-2025)
6.1.2 North America PD-1 and PD-L1 Inhibitors Sales Breakdown by Type (2020-2025)
6.1.3 North America PD-1 and PD-L1 Inhibitors Sales Breakdown by Application (2020-2025)
6.1.4 North America PD-1 and PD-L1 Inhibitors Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe PD-1 and PD-L1 Inhibitors Sales by Company
6.2.1.1 Europe PD-1 and PD-L1 Inhibitors Sales by Company (2020-2025)
6.2.1.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Company (2020-2025)
6.2.2 Europe PD-1 and PD-L1 Inhibitors Sales Breakdown by Type (2020-2025)
6.2.3 Europe PD-1 and PD-L1 Inhibitors Sales Breakdown by Application (2020-2025)
6.2.4 Europe PD-1 and PD-L1 Inhibitors Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 Japan Market: Players, Segments, Downstream and Major Customers
6.3.1 Japan PD-1 and PD-L1 Inhibitors Sales by Company
6.3.1.1 Japan PD-1 and PD-L1 Inhibitors Sales by Company (2020-2025)
6.3.1.2 Japan PD-1 and PD-L1 Inhibitors Revenue by Company (2020-2025)
6.3.2 Japan PD-1 and PD-L1 Inhibitors Sales Breakdown by Type (2020-2025)
6.3.3 Japan PD-1 and PD-L1 Inhibitors Sales Breakdown by Application (2020-2025)
6.3.4 Japan PD-1 and PD-L1 Inhibitors Major Customer
6.3.5 Japan Market Trend and Opportunities
6.4 China Market: Players, Segments, Downstream and Major Customers
6.4.1 China PD-1 and PD-L1 Inhibitors Sales by Company
6.4.1.1 China PD-1 and PD-L1 Inhibitors Sales by Company (2020-2025)
6.4.1.2 China PD-1 and PD-L1 Inhibitors Revenue by Company (2020-2025)
6.4.2 China PD-1 and PD-L1 Inhibitors Sales Breakdown by Type (2020-2025)
6.4.3 China PD-1 and PD-L1 Inhibitors Sales Breakdown by Application (2020-2025)
6.4.4 China PD-1 and PD-L1 Inhibitors Major Customer
6.4.5 China Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Business Overview
7.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Merck PD-1 and PD-L1 Inhibitors Products Offered
7.1.5 Merck Recent Development
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Company Information
7.2.2 Bristol-Myers Squibb Business Overview
7.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
7.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Products Offered
7.2.5 Bristol-Myers Squibb Recent Development
7.3 Roche
7.3.1 Roche Company Information
7.3.2 Roche Business Overview
7.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Roche PD-1 and PD-L1 Inhibitors Products Offered
7.3.5 Roche Recent Development
7.4 AstraZeneca
7.4.1 AstraZeneca Company Information
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
7.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Products Offered
7.4.5 AstraZeneca Recent Development
7.5 Ono Pharmaceutical
7.5.1 Ono Pharmaceutical Company Information
7.5.2 Ono Pharmaceutical Business Overview
7.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Products Offered
7.5.5 Ono Pharmaceutical Recent Development
7.6 Regeneron
7.6.1 Regeneron Company Information
7.6.2 Regeneron Business Overview
7.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Regeneron PD-1 and PD-L1 Inhibitors Products Offered
7.6.5 Regeneron Recent Development
7.7 Innovent
7.7.1 Innovent Company Information
7.7.2 Innovent Business Overview
7.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Innovent PD-1 and PD-L1 Inhibitors Products Offered
7.7.5 Innovent Recent Development
7.8 Hengrui Medicine
7.8.1 Hengrui Medicine Company Information
7.8.2 Hengrui Medicine Business Overview
7.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
7.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Products Offered
7.8.5 Hengrui Medicine Recent Development
7.9 Junshi Biosciences
7.9.1 Junshi Biosciences Company Information
7.9.2 Junshi Biosciences Business Overview
7.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
7.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Products Offered
7.9.5 Junshi Biosciences Recent Development
7.10 Merck KGaA
7.10.1 Merck KGaA Company Information
7.10.2 Merck KGaA Business Overview
7.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
7.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Products Offered
7.10.5 Merck KGaA Recent Development
8 PD-1 and PD-L1 Inhibitors Manufacturing Cost Analysis
8.1 PD-1 and PD-L1 Inhibitors Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of PD-1 and PD-L1 Inhibitors
8.4 PD-1 and PD-L1 Inhibitors Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 PD-1 and PD-L1 Inhibitors Distributors List
9.3 PD-1 and PD-L1 Inhibitors Customers
10 PD-1 and PD-L1 Inhibitors Market Dynamics
10.1 PD-1 and PD-L1 Inhibitors Industry Trends
10.2 PD-1 and PD-L1 Inhibitors Market Drivers
10.3 PD-1 and PD-L1 Inhibitors Market Challenges
10.4 PD-1 and PD-L1 Inhibitors Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
List of Tables
Table 1. Global PD-1 and PD-L1 Inhibitors Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global PD-1 and PD-L1 Inhibitors Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)
Table 3. Global Market PD-1 and PD-L1 Inhibitors Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global PD-1 and PD-L1 Inhibitors Sales (K Dose) by Region (2020-2025)
Table 5. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2020-2025)
Table 6. Global PD-1 and PD-L1 Inhibitors Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global PD-1 and PD-L1 Inhibitors Revenue Share by Region (2020-2025)
Table 8. Global PD-1 and PD-L1 Inhibitors Sales (K Dose) Forecast by Region (2026-2031)
Table 9. Global PD-1 and PD-L1 Inhibitors Sales Market Share Forecast by Region (2026-2031)
Table 10. Global PD-1 and PD-L1 Inhibitors Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global PD-1 and PD-L1 Inhibitors Revenue Share Forecast by Region (2026-2031)
Table 12. Global PD-1 and PD-L1 Inhibitors Sales by Type (K Dose) & (2020-2025)
Table 13. Global PD-1 and PD-L1 Inhibitors Sales Share by Type (2020-2025)
Table 14. Global PD-1 and PD-L1 Inhibitors Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global PD-1 and PD-L1 Inhibitors Price by Type (US$/Dose) & (2020-2025)
Table 16. Global PD-1 and PD-L1 Inhibitors Sales by Type (K Dose) & (2026-2031)
Table 17. Global PD-1 and PD-L1 Inhibitors Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global PD-1 and PD-L1 Inhibitors Price by Type (US$/Dose) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global PD-1 and PD-L1 Inhibitors Sales by Application (K Dose) & (2020-2025)
Table 21. Global PD-1 and PD-L1 Inhibitors Sales Share by Application (2020-2025)
Table 22. Global PD-1 and PD-L1 Inhibitors Revenue by Application (US$ Million) & (2020-2025)
Table 23. Global PD-1 and PD-L1 Inhibitors Price by Application (US$/Dose) & (2020-2025)
Table 24. Global PD-1 and PD-L1 Inhibitors Sales by Application (K Dose) & (2026-2031)
Table 25. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (US$ Million) & (2026-2031)
Table 26. Global PD-1 and PD-L1 Inhibitors Price by Application (US$/Dose) & (2026-2031)
Table 27. New Sources of Growth in PD-1 and PD-L1 Inhibitors Application
Table 28. Global PD-1 and PD-L1 Inhibitors Sales by Company (K Dose) & (2020-2025)
Table 29. Global PD-1 and PD-L1 Inhibitors Sales Share by Company (2020-2025)
Table 30. Global PD-1 and PD-L1 Inhibitors Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global PD-1 and PD-L1 Inhibitors Revenue Share by Company (2020-2025)
Table 32. Global PD-1 and PD-L1 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Inhibitors as of 2024)
Table 33. Global Market PD-1 and PD-L1 Inhibitors Average Price by Company (US$/Dose) & (2020-2025)
Table 34. Global Key Manufacturers of PD-1 and PD-L1 Inhibitors, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of PD-1 and PD-L1 Inhibitors, Product Type & Application
Table 36. Global Key Manufacturers of PD-1 and PD-L1 Inhibitors, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America PD-1 and PD-L1 Inhibitors Sales by Company (2020-2025) & (K Dose)
Table 39. North America PD-1 and PD-L1 Inhibitors Sales Market Share by Company (2020-2025)
Table 40. North America PD-1 and PD-L1 Inhibitors Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America PD-1 and PD-L1 Inhibitors Revenue Market Share by Company (2020-2025)
Table 42. North America PD-1 and PD-L1 Inhibitors Sales by Type (2020-2025) & (K Dose)
Table 43. North America PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2020-2025)
Table 44. North America PD-1 and PD-L1 Inhibitors Sales by Application (2020-2025) & (K Dose)
Table 45. North America PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2020-2025)
Table 46. Europe PD-1 and PD-L1 Inhibitors Sales by Company (2020-2025) & (K Dose)
Table 47. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Company (2020-2025)
Table 48. Europe PD-1 and PD-L1 Inhibitors Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe PD-1 and PD-L1 Inhibitors Revenue Market Share by Company (2020-2025)
Table 50. Europe PD-1 and PD-L1 Inhibitors Sales by Type (2020-2025) & (K Dose)
Table 51. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2020-2025)
Table 52. Europe PD-1 and PD-L1 Inhibitors Sales by Application (2020-2025) & (K Dose)
Table 53. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2020-2025)
Table 54. Japan PD-1 and PD-L1 Inhibitors Sales by Company (2020-2025) & (K Dose)
Table 55. Japan PD-1 and PD-L1 Inhibitors Sales Market Share by Company (2020-2025)
Table 56. Japan PD-1 and PD-L1 Inhibitors Revenue by Company (2020-2025) & (US$ Million)
Table 57. Japan PD-1 and PD-L1 Inhibitors Revenue Market Share by Company (2020-2025)
Table 58. Japan PD-1 and PD-L1 Inhibitors Sales by Type (2020-2025) & (K Dose)
Table 59. Japan PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2020-2025)
Table 60. Japan PD-1 and PD-L1 Inhibitors Sales by Application (2020-2025) & (K Dose)
Table 61. Japan PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2020-2025)
Table 62. China PD-1 and PD-L1 Inhibitors Sales by Company (2020-2025) & (K Dose)
Table 63. China PD-1 and PD-L1 Inhibitors Sales Market Share by Company (2020-2025)
Table 64. China PD-1 and PD-L1 Inhibitors Revenue by Company (2020-2025) & (US$ Million)
Table 65. China PD-1 and PD-L1 Inhibitors Revenue Market Share by Company (2020-2025)
Table 66. China PD-1 and PD-L1 Inhibitors Sales by Type (2020-2025) & (K Dose)
Table 67. China PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2020-2025)
Table 68. China PD-1 and PD-L1 Inhibitors Sales by Application (2020-2025) & (K Dose)
Table 69. China PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2020-2025)
Table 70. Merck Company Information
Table 71. Merck Description and Business Overview
Table 72. Merck PD-1 and PD-L1 Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 73. Merck PD-1 and PD-L1 Inhibitors Product
Table 74. Merck Recent Development
Table 75. Bristol-Myers Squibb Company Information
Table 76. Bristol-Myers Squibb Description and Business Overview
Table 77. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 78. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product
Table 79. Bristol-Myers Squibb Recent Development
Table 80. Roche Company Information
Table 81. Roche Description and Business Overview
Table 82. Roche PD-1 and PD-L1 Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 83. Roche PD-1 and PD-L1 Inhibitors Product
Table 84. Roche Recent Development
Table 85. AstraZeneca Company Information
Table 86. AstraZeneca Description and Business Overview
Table 87. AstraZeneca PD-1 and PD-L1 Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 88. AstraZeneca PD-1 and PD-L1 Inhibitors Product
Table 89. AstraZeneca Recent Development
Table 90. Ono Pharmaceutical Company Information
Table 91. Ono Pharmaceutical Description and Business Overview
Table 92. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 93. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product
Table 94. Ono Pharmaceutical Recent Development
Table 95. Regeneron Company Information
Table 96. Regeneron Description and Business Overview
Table 97. Regeneron PD-1 and PD-L1 Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 98. Regeneron PD-1 and PD-L1 Inhibitors Product
Table 99. Regeneron Recent Development
Table 100. Innovent Company Information
Table 101. Innovent Description and Business Overview
Table 102. Innovent PD-1 and PD-L1 Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 103. Innovent PD-1 and PD-L1 Inhibitors Product
Table 104. Innovent Recent Development
Table 105. Hengrui Medicine Company Information
Table 106. Hengrui Medicine Description and Business Overview
Table 107. Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 108. Hengrui Medicine PD-1 and PD-L1 Inhibitors Product
Table 109. Hengrui Medicine Recent Development
Table 110. Junshi Biosciences Company Information
Table 111. Junshi Biosciences Description and Business Overview
Table 112. Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 113. Junshi Biosciences PD-1 and PD-L1 Inhibitors Product
Table 114. Junshi Biosciences Recent Development
Table 115. Merck KGaA Company Information
Table 116. Merck KGaA Description and Business Overview
Table 117. Merck KGaA PD-1 and PD-L1 Inhibitors Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 118. Merck KGaA PD-1 and PD-L1 Inhibitors Product
Table 119. Merck KGaA Recent Development
Table 120. Production Base and Market Concentration Rate of Raw Material
Table 121. Key Suppliers of Raw Materials
Table 122. PD-1 and PD-L1 Inhibitors Distributors List
Table 123. PD-1 and PD-L1 Inhibitors Customers List
Table 124. PD-1 and PD-L1 Inhibitors Market Trends
Table 125. PD-1 and PD-L1 Inhibitors Market Drivers
Table 126. PD-1 and PD-L1 Inhibitors Market Challenges
Table 127. PD-1 and PD-L1 Inhibitors Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources


List of Figures
Figure 1. PD-1 and PD-L1 Inhibitors Product Picture
Figure 2. Global PD-1 and PD-L1 Inhibitors Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type in 2024 & 2031
Figure 4. PD-1 Inhibitors Product Picture
Figure 5. PD-L1 Inhibitors Product Picture
Figure 6. Global PD-1 and PD-L1 Inhibitors Sales (US$ Million) by Application (2020 & 2024 & 2031)
Figure 7. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application in 2024 & 2031
Figure 8. Solid Tumors Examples
Figure 9. Blood-related Tumors Examples
Figure 10. Global PD-1 and PD-L1 Inhibitors Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global PD-1 and PD-L1 Inhibitors Sales Growth Rate (2020-2031) & (US$ Million)
Figure 12. Global PD-1 and PD-L1 Inhibitors Sales (K Dose) Growth Rate (2020-2031)
Figure 13. Global PD-1 and PD-L1 Inhibitors Price Trends Growth Rate (2020-2031) & (US$/Dose)
Figure 14. PD-1 and PD-L1 Inhibitors Report Years Considered
Figure 15. Global Market PD-1 and PD-L1 Inhibitors Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 16. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region: 2020 VS 2024
Figure 17. North America PD-1 and PD-L1 Inhibitors Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. North America PD-1 and PD-L1 Inhibitors Sales (K Dose) Growth Rate (2020-2031)
Figure 19. Europe PD-1 and PD-L1 Inhibitors Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. Europe PD-1 and PD-L1 Inhibitors Sales (K Dose) Growth Rate (2020-2031)
Figure 21. Japan PD-1 and PD-L1 Inhibitors Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. Japan PD-1 and PD-L1 Inhibitors Sales (K Dose) Growth Rate (2020-2031)
Figure 23. China PD-1 and PD-L1 Inhibitors Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. China PD-1 and PD-L1 Inhibitors Sales (K Dose) Growth Rate (2020-2031)
Figure 25. Global PD-1 and PD-L1 Inhibitors Revenue Share by Type (2020-2025)
Figure 26. Global PD-1 and PD-L1 Inhibitors Sales Share by Type (2026-2031)
Figure 27. Global PD-1 and PD-L1 Inhibitors Revenue Share by Type (2026-2031)
Figure 28. Global PD-1 and PD-L1 Inhibitors Revenue Share by Application (2020-2025)
Figure 29. Global PD-1 and PD-L1 Inhibitors Revenue Growth Rate by Application in 2020 & 2024
Figure 30. Global PD-1 and PD-L1 Inhibitors Sales Share by Application (2026-2031)
Figure 31. Global PD-1 and PD-L1 Inhibitors Revenue Share by Application (2026-2031)
Figure 32. Global PD-1 and PD-L1 Inhibitors Sales Share by Company (2024)
Figure 33. Global PD-1 and PD-L1 Inhibitors Revenue Share by Company (2024)
Figure 34. Global 5 Largest PD-1 and PD-L1 Inhibitors Players Market Share by Revenue in PD-1 and PD-L1 Inhibitors: 2020 & 2024
Figure 35. PD-1 and PD-L1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 36. Manufacturing Cost Structure of PD-1 and PD-L1 Inhibitors
Figure 37. Manufacturing Process Analysis of PD-1 and PD-L1 Inhibitors
Figure 38. PD-1 and PD-L1 Inhibitors Industrial Chain
Figure 39. Channels of Distribution (Direct Vs Distribution)
Figure 40. Distributors Profiles
Figure 41. Bottom-up and Top-down Approaches for This Report
Figure 42. Data Triangulation
Figure 43. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies